 Adaptimmune Therapeutics plc NASDAQ: ADAP revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel afami-cel, formerly ADP-A2M4. Data will be presented at the American Society of Clinical Oncology ASCO congress. 